{
"id":"mk19_a_on_t12",
"number":12,
"bookId":"on",
"title":{
"__html":"Treatments for Metastatic Prostate Cancer"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"983a65",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 12. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_on_t12"
}
]
},
"Treatments for Metastatic Prostate Cancer"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bd813",
"class":"col hd l",
"children":[
"Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"375099",
"class":"col hd l",
"children":[
"Agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6cdc4b",
"class":"col hd l",
"children":[
"Mechanism of Action"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b670b8",
"class":"col hd l",
"children":[
"Indications"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4d0cc",
"class":"cell txt l",
"children":[
"GnRH agonist"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c5e9cd",
"class":"cell txt l",
"children":[
"Leuprolide, goserelin, triptorelin, buserelin, histrelin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35be4d",
"class":"cell txt l",
"children":[
"Binds to GnRH receptor, causes initial release of FSH/LH (and also testosterone) followed by suppression"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6922a0",
"class":"cell txt l",
"children":[
"Metastatic prostate cancer; neoadjuvant/adjuvant ADT alone or in combination with radiation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e3594",
"class":"cell txt l",
"children":[
"GnRH antagonist"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd4c21",
"class":"cell txt l",
"children":[
"Degarelix, relugolix"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"adfe49",
"class":"cell txt l",
"children":[
"Binds to GnRH receptor and suppresses activity without initial increase in activity seen with GnRH agonists"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6922a0",
"class":"cell txt l",
"children":[
"Metastatic prostate cancer; neoadjuvant/adjuvant ADT alone or in combination with radiation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1fd8bd",
"class":"cell txt l",
"children":[
"Antiandrogen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa9205",
"class":"cell txt l",
"children":[
"Bicalutamide, flutamide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c0c2fe",
"class":"cell txt l",
"children":[
"Binds to androgen receptor with competitive inhibition of testosterone binding"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c1e934",
"class":"cell txt l",
"children":[
"Metastatic castrate-sensitive prostate cancer (not indicated as monotherapy, only in combination with GnRH agonist or antagonist)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"80c2a9",
"class":"cell txt l",
"children":[
"CYP17 inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"815e9f",
"class":"cell txt l",
"children":[
"Abiraterone plus prednisone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32b09a",
"class":"cell txt l",
"children":[
"Blocks androgen synthesis in tumor tissue, testes, and adrenal glands"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"900fb7",
"class":"cell txt l",
"children":[
"De novo metastatic castrate-sensitive prostate cancer; metastatic castrate-resistant prostate cancer; locally advanced nonmetastatic prostate cancer; used in combination with prednisone as it can cause adrenal insufficiency"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52e121",
"class":"cell txt l",
"children":[
"Androgen receptor blockade"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fbdf76",
"class":"cell txt l",
"children":[
"Enzalutamide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d487d",
"class":"cell txt l",
"children":[
"Binds to the androgen binding site of the androgen receptor in a noncompetitive fashion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ff219",
"class":"cell txt l",
"children":[
"De novo metastatic castrate-sensitive prostate cancer or castrate-sensitive metastatic cancer following prostatectomy, radiation, or ADT therapy; castrate-resistant prostate cancer and M0 castrate-resistant prostate cancer"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52e121",
"class":"cell txt l",
"children":[
"Androgen receptor blockade"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c46ce2",
"class":"cell txt l",
"children":[
"Apalutamide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e633f",
"class":"cell txt l",
"children":[
"Same as enzalutamide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"270908",
"class":"cell txt l",
"children":[
"De novo metastatic castrate-sensitive cancer or metastatic castrate-sensitive cancer following prostatectomy, radiation therapy; M0 castrate-resistant prostate cancer"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"48a387",
"class":"cell txt l",
"children":[
"Tumor vaccine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"28a34a",
"class":"cell txt l",
"children":[
"Sipuleucel-T"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8df994",
"class":"cell txt l",
"children":[
"Autologous dendritic cell therapeutic vaccine"
]
},
" ",
{
"type":"p",
"hlId":"e8ec2c",
"class":"cell txt l",
"children":[
"Aims to increase T-cell response to prostatic acid phosphatase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d5ed8b",
"class":"cell txt l",
"children":[
"Asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer with no visceral metastatic disease"
]
},
" ",
{
"type":"p",
"hlId":"23ccd3",
"class":"cell txt l",
"children":[
"Not indicated for PSA-only relapse; does not result in PSA response"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"211363",
"class":"cell txt l",
"children":[
"Bone-seeking isotope"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e6357c",
"class":"cell txt l",
"children":[
"Radium-223"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0acae8",
"class":"cell txt l",
"children":[
"Alpha particle–emitting isotope that concentrates in bone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8918b3",
"class":"cell txt l",
"children":[
"Metastatic castrate-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cf3856",
"class":"cell txt l",
"children":[
"Chemotherapeutic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"930e07",
"class":"cell txt l",
"children":[
"Docetaxel plus prednisone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7fbb1d",
"class":"cell txt l",
"children":[
"Antimicrotubule agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5101fd",
"class":"cell txt l",
"children":[
"Metastatic castrate-resistant prostate cancer with clinical metastatic disease"
]
},
" ",
{
"type":"p",
"hlId":"84cba0",
"class":"cell txt l",
"children":[
"Metastatic castrate-sensitive prostate cancer in combination with ADT in men with high-volume",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" clinical metastatic disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cf3856",
"class":"cell txt l",
"children":[
"Chemotherapeutic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9c819c",
"class":"cell txt l",
"children":[
"Cabazitaxel plus prednisone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7fbb1d",
"class":"cell txt l",
"children":[
"Antimicrotubule agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"982feb",
"class":"cell txt l",
"children":[
"Metastatic castrate-resistant prostate cancer following disease progression after docetaxel treatment"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Visceral metastases and ≥1 bone lesion, or ≥4 bone lesions with ≥1 outside the axial skeleton"
],
[
"ADT = androgen-deprivation therapy; CYP17 = 17α-hydroxy/17,20-lyase; FSH = follicle-stimulating hormone; GnRH = gonadotropin-releasing hormone; LH = luteinizing hormone; M0 = without evidence of distant metastasis; PSA = prostate-specific antigen."
]
]
}